You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Kite and Refuge Biotechnologies to work together to research blood cancer

Kite – a Gilead Company – has entered into an exclusive, worldwide licence agreement with Refuge Biotechnologies (Refuge), a synthetic biology company for cancer immunotherapy.